United Therapeutics Says Pulmonary Arterial Hypertension Treatment Meets Primary Endpoint in Late-Stage Trial
MT Newswires Live
May 18
United Therapeutics' (UTHR) phase 3 trial of ralinepag in patients with pulmonary arterial hypertension met its primary endpoint, the company said Sunday.
The treatment cut the risk of clinical worsening events by 55%, compared with placebo, with secondary endpoints also demonstrating favorable outcomes, the company said.
United Therapeutics plans to file a new drug application with the US Food and Drug Administration for ralinepag in H2 2026.
Pulmonary arterial hypertension is a life-threatening disease that impacts the blood vessels in the lungs and is characterized by increased pressure in the pulmonary arteries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.